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Context: The indeterminate multiparametric prostate magnetic resonance image 
(mpMRI) lesion is one which cannot be classified as “positive” or “negative” for suspected 
cancer. Currently, there is no consensus on how to manage patients with indeterminate 
mpMRIs, where areas cannot be classified as positives or negatives (PI-RADS 3 or Likert 3). 
Objective: to define the concept of the indeterminate lesion and describe what 
management strategies may be adopted for these patients.  
Evidence acquisition: A literature search of the PubMed database was carried out 
including the search terms “prostate indeterminate lesions”, “PIRADS 3”, “Likert 3”, 
“magnetic resonance imaging”, “prostate cancer”.  
Evidence synthesis: There is no universally accepted definition of what constitutes an 
indeterminate lesion on mpMRI. This is in part due to the experience of the reporting 
radiologist and their willingness to call a lesion indeterminate, knowing that this may have 
consequences for biopsy decisions. This is also in part due to the significant variation in 
mpMRI acquisition parameters used between different sites. Strategies for managing the 
indeterminate lesion include: 1) Biopsy, where there is a highly variable prevalence of 
prostate cancer (PCa), reflecting the differences in clinically significant PCa definitions, 
mpMRI protocols and inter-observer variability in characterization of indeterminate lesions 
and 2) Surveillance, where early results suggest that this strategy may be of value for some 
selected patients with PSA monitoring and/or interval mpMRI. The use of pre-biopsy MRI, in 
conjunction with traditional clinical parameters and secondary biomarkers-nomograms, may 
allow a more accurate selection of patients who can avoid biopsy. 
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Conclusion: A strategy of close surveillance based on PSA monitoring and interval 
mpMRI is a feasible management option for motivated patients with the indeterminate 
mpMRI. This surveillance strategy could result in fewer men needing to undergo biopsy and 
though early results are promising, long-term results for such a strategy are awaited. 
Patient summary: In some patients who have an MRI scan of their prostate, the scan 
may identify an area that we are not sure contains cancer or not. This area is typically called 
the “indeterminate” lesion. In this report we looked to define the concept of the 
indeterminate lesion on multiparametric magnetic resonance (mpMRI) and describe what 
strategies may be carried out for these patients. The use of mpMRI, in conjunction with 
traditional clinical parameters, may allow more accurate risk stratification and assessment 














  Prostate specific antigen (PSA) testing is the main triage test for detection of 
prostate cancer (PCa). However, PSA has limited specificity and sensitivity in determining 
the presence of PCa, leading to unnecessary biopsies and the diagnosis of potentially 
indolent PCa. The current standard of care diagnostic procedure for men with suspected 
PCa is transrectal ultrasound guided biopsy (TRUS-bx). For a prostate volume of 30–40 mL, 
10–12 core biopsies are recommended (1). Unlike many other solid tumours for which 
image-guided biopsy is common, PCa has traditionally been detected by randomly sampling 
the organ.  
However, the recent introduction of multiparametric magnetic resonance imaging 
(mpMRI) allows for image-based identification, which may improve diagnostic accuracy for 
high risk PCa. Advances in imaging have led to the development of fusion biopsy platforms 
in which mpMRI images are electronically superimposed in real time on transrectal 
ultrasound (TRUS) images. Numerous targeted biopsy platforms exist and can perform 
biopsies of suspicious regions seen on the prostate mpMRI. (2-6)  
The translation into clinical practice of the results on mpMRI findings is important. A 
mpMRI which does not identify any suspicious areas is associated with a high negative 
predictive value (NPV) for clinically significant disease and could avoid many unnecessary 
biopsies (7). A positive finding allows a suspicious area to be targeted with higher sampling 
density, which may result in a greater proportion of men diagnosed with clinically significant 
disease (8).  
Currently, there is no consensus on what to do in the case of the appearance of 
indeterminate lesions on mpMRI, where areas cannot be classified as positives or negatives 
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(e.g. PI-RADS score of 3 or Likert score of 3). A recent retrospective study of men with 
indeterminate lesions on MRI shows that when offered a choice of immediate biopsy or 
surveillance, men preferred surveillance, with 57% choosing this option. The overall 
proportion of men with clinically significant PCa in this cohort was 14%. Whilst immediate 
biopsy is an option for these men, surveillance of the lesion is another possibility. (9) 
The objective of this review is to define the concept of the indeterminate lesion and 
describe what strategies may be carried out for these patients.  
 
EVIDENCE ACQUISITION 
A literature search was carried out using the PubMed database, including the 
following search terms “PI-RADS 3”, “LIKERT 3”, “magnetic resonance imaging”, “prostate 
cancer”, “prostate indeterminate lesions”. Relevant original articles and reviews were 
identified. Abstracts presented congresses were excluded. Studies with the highest level of 
evidence and relevance to the discussed topics were selected with the consensus of the 
authors. 
 
EVIDENCE SYNTHESIS  
CONCEPT OF THE INDETERMINATE LESION AND PERCENTAGE OF INDETERMINATE LESIONS 
DETECTED ON mpMRI. 
mpMRI is increasingly being used in the detection and management of PCa. This 
technique is able to detect both high grade and large tumours (i.e. clinically significant 
cancer) accurately. There is growing evidence that mpMRI has the potential to discriminate 
between low-and intermediate/high-grade PCa (10).   
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However, mpMRI faces a number of challenges, one of which is determining the 
definition of the indeterminate lesion on mpMRI (11). The learning curve in prostate MRI 
interpretation is well recognized and recent findings have noted improvements over time in 
the accuracy of clinical interpretations after the implementation of prostate MRI at various 
centres (12,13). There is also variation in the reporting radiologists’ willingness to assign an 
indeterminate status to a lesion, knowing that this might influence the decision to perform a 
biopsy. This can change for a particular radiologist over time, as experience changes. 
Despite continual progress in prostate MRI interpretation within the radiologic community, 
achieving accurate and consistent interpretations continues to provide a challenge. 
Although PI-RADS is intended to facilitate education and improve reader performance, the 
system itself requires training. The overall importance of reader experience for radiologists’ 
performance in prostate MRI interpretation has been well characterized (14,15). However, 
the optimal strategy for educating radiologists in prostate MRI and reducing this learning 
curve is yet to be identified.   
It is well known that an accurate mapping of cancer foci is crucial to evaluate tumour 
burden accurately, in order to allow an adequate treatment for men with PCa. In this 
regard, there is consensus among radiologists that the usage of a 5-point scale (Likert or PI-
RADS) is very important to assess the likelihood of having clinically significant cancer, with a 
score of 3 out of 5 representing an indeterminate area that is suspicious for clinically 
significant cancer (16-17). The Likert score, rather than providing fixed criteria, is a 
subjective scale which is strictly linked to the overall impression of the reporting radiologist 
(Figure 1 and 2). Conversely, the PI-RADS criteria represent an attempt to overcome such 
variability, as they give the possibility to generate a score applying fixed criteria in order to 
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improve the agreement between different radiologists. Both approaches have been shown 
to be comparable (18-19). The criteria chosen might also depend on the technical standard 
of the MRI-scanner; the pulse sequences/scanning time and the parameters used. PI-
RADSv2 made an attempt to define diagnostic parameters, but there is variation in clinical 
practice is common due to variation in MRI scanners used and local resources available.  
The current definition of indeterminate lesion on mpMRI is not well described in 
literature, although PI-RADSv2 classification defines it as a heterogeneous signal intensity or 
non-circumscribed, rounded with moderate hypointensity in the T2-weighted imaging in the 
peripheral zone; a heterogeneous signal intensity with obscured margins in transition zone 
and focal mildly/moderately hypointense on ADC and isointense/mildly hyperintense on 
high b-value in the diffusion-weighted imaging. Also, PI-RADS classification states that 
indeterminate lesions include others that do not qualify as 2, 4, or 5. (17) 
In summary, there is no universally accepted definition of what criteria constitute an 
indeterminate lesion on mpMRI as this can vary according to a number of factors. However 
scoring systems such as PIRADSv2 have been developed to overcome the variability in 
ascribing scores and future versions of this scoring system may help provide further clarity 
on this matter (13, 20).  
The PROMIS study has recently shown that in a group of biopsy-naïve men, the 
likelihood of having an indeterminate lesion is 28% (18). There is also evidence that an 
accurate strategy for targeting mpMRI lesions that have been scored as indeterminate but 
might have a real likelihood of harbouring clinically significant PCa is of utmost importance, 
as this may reduce the burden of overdiagnosis and overtreatment (21). 
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INDETERMINATE LESIONS: WHAT TO DO? 
a) Biopsy 
 Currently, a random systematic 10 to 12 core transperineal or TRUS-bx is the 
standard of care for the diagnosis of PCa in men with rising PSA and/or suspicious digital 
rectal examination (DRE) (1). However, standard TRUS-bx performs poorly for detecting 
clinically significant PCa, particularly in the anterior part of the prostate, and up to 70% of 
patients undergoing initial prostate biopsy have negative results. (22-23) 
 After an initial negative biopsy and in the persistent clinical suspicion of PCa, 
contemporary guidelines recommend performing a mpMRI before repeat biopsy (1). mpMRI 
targeted biopsies may detect clinically significant PCa in up to 54% of patients, having a 
higher detection rate comparing to standard systematic biopsies. (2-6). In this group of men, 
systematic plus imaging-targeted biopsies for PI-RADS 4-5 lesions (at least two cores from 
each MRI defined target) were recommended, while it was recommended that biopsy could 
be avoided for PIRADS 1-2 lesions (2). However, PI-RADS 3 lesions are indeterminate for the 
presence of clinically significant PCa which may lead to challenging situation to manage.  
 Sonn et al. (24) prospectively reviewed 105 patients with ≥ 1 prior negative prostate 
biopsy and clinical suspicion of PCa who underwent mpMRI and mpMRI-ultrasound fusion 
biopsy. Eighty-four PI-RADS 3 lesions were identified of which only 5% had PCa (4% 
significant PCa). In the same setting, a retrospective analysis from Kaufmann et al. (25) 
demonstrated a detection rate of PCa of 33% (5/15) among patients with PI-RADS 3 
assessment. In the literature, there is a highly variable prevalence of PCa associated with PI-
RADS 3 lesions, reflecting the differences in clinically significant PCa definitions, mpMRI 
protocols and inter-observer variability in characterization of PI-RADS 3 lesions.  
9 
 
 There is increasing evidence on the use of pre-biopsy mpMRI in biopsy-naïve 
patients and mpMRI is increasingly being performed as a triage test to avoid unnecessary 
biopsies and to improve detection of clinically significant PCa while avoiding detection of 
low-grade disease (21,26). In this setting, some studies report detection rates of PCa among 
biopsied PI-RADS 3 lesions from 6.5% to 22%, with significant PCa being detected in 4.4% to 
11.3% (27-29). In a study by Porpiglia et al (30), patients with PI-RADS score 3 lesions who 
underwent mpMRI/transrectal ultrasound fusion software-guided targeted biopsy had 
12.5% (3/24) overall detection of PCa and 3/24 (12.5%) detection of clinically significant PCa. 
 Some available adjuncts may be of additional value in the presence of an 
indeterminate MRI to help make a decision as whether to proceed with prostate biopsy 
(31). When PI-RADS score and PSA density were combined, PI-RADS 3 score or greater and 
PSA density of ≥0.30 ng/mL/mL (high-risk group) was associated with the highest clinically 
significant PCa detection rates (86%). On the other hand, PI-RADS 3 and PSA density of <0.15 
ng/mL/mL (low-risk group) detected 0% of clinically significant PCa, which may suggest that 
these patients could have avoided unnecessary initial biopsies (32).  
 
b) Surveillance of the lesion 
 There is a paucity of literature and evidence regarding surveillance on PI-RADS 3 
lesions on mpMRI of the prostate. Although a prostate biopsy is generally recommended, 
follow-up mpMRI may be an alternative option in the management of these patients. 
 Hauth et al. (33) retrospectively determined the rate of malignancy after follow-up 
mpMRI of the prostate in 46 patients with suspected PCa and PI-RADS 3 assessment in a 
baseline prostatic mpMRI without core biopsy. Follow-up mpMRI was performed, on 
average, after 22.6 months. Forty eight percent (22/46) of lesions had smaller diameter 
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and/or decreased suspicious functional parameters, being down-graded to a PI-RADS score 
of 2 with subsequent clinical follow up in one year. Forty eight percent (22/46) of PI-RADS 3 
lesions remained stable with a second follow-up mpMRI recommended in two years. Only 
4% (2/46) were progressive lesions (defined as an increase in diameter and/or in suspicious 
functional parameters), re-assessed to PI-RADS 4. TRUS-bx was performed and revelled PCa 
Gleason score 7 in both patients. Compared to patients with PI-RADS 4 score and an initial 
negative prostate biopsy, which had a rate of malignancy of 69% in re-biopsy, PI-RADS 3 
lesions had a low malignancy rate, meaning that follow-up these patients seemed to be a 
reasonable alternative to biopsy. 
 In a study published by van der Sar et al (9), 168 patients with Likert score 3/5 lesions 
on mpMRI, without a previous prostate biopsy, were able to choose between immediate 
biopsy and surveillance on the lesion with delayed biopsy if necessary. The majority of 
patients (57%; 95/168) chose surveillance with PSA and/or mpMRI at 6-12months intervals. 
During follow-up, biopsy was performed in 11% (10/95) due to rising PSA and/or 
progression on mpMRI. Of these, 4% (4/95) had PCa, all Gleason 3+4, and underwent 
treatment with curative intent. In the immediate biopsy group PCa was detected in 45% 
(33/73) and clinically significant PCa in 26% (19/73). In this study, indeterminate lesions on 
mpMRI did not have features of high-risk disease and risk profile for cancers detected was 
similar between both groups. 
 Although early results suggest that a surveillance strategy may be of value for some 
selected patients, long-term outcomes and large cohorts are needed before firm 




HELPFUL TOOLS IN THE SETTING OF PATIENTS WITH INDETERMINATE LESIONS ON mpMRI 
(NOMOGRAMS-BIOMARKERS) 
Nomograms and biomarkers have been enhanced to incorporate mpMRI findings to 
predict both overall and clinically significant cancer risk, which allows for counseling men on 
the need for biopsy. New biomarkers, such as kallikrein panels (4K Score® and Prostate 
Health Index®) and urine biomarkers (PCA3 and TMPRSS2-ERG), may improve further upon 
existing PCa screening, detection, and risk assessment tools (31). The implementation of 
these biomarkers as secondary tools in conjunction with mpMRI could improve specificity 
markedly, sparing as many as half of men with an elevated PSA the need to undergo biopsy. 
Fenstermaker et al. (34) evaluated whether a combination of PCA3 and mpMRI 
suspicion score could further optimize the detection of PCa on MRI fusion- targeted biopsy 
among men with no history of biopsy. Their results showed that PCA3 <35 demonstrates a 
high NPV among MRI suspicion score 2-3. However, in the case of high-suspicion mpMRI, 
PCA3 was not associated with cancer detection on mpMRI-ultrasound-fusion targeted 
biopsy, not adding value to cancer diagnosis. By biopsying men with a mpMRI suspicion 
score of 4-5 and obtaining PCA3 on men with a mpMRI suspicion score of 2-3, followed by 
biopsy only in men with PCA3 score >35, 36.1% of biopsies would be avoided, and 4.9% of 
Gleason score ≥3+4 cancers would have been missed. Other ancillary markers may help 
select patients with a negative/low-suspicion MRI for systematic biopsy. 
Recently, nomograms have substantially improved predictive accuracy for both 
endpoints, even in diverse populations as well as in patients with no prior biopsy or with a 
prior negative biopsy. Bjurlin et al. (35) developed a nomogram to predict the probability of 
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Gleason score 7 on mpMRI targeted and systematic prostate biopsy in biopsy naive patients. 
mpMRI-utrasound fusion targeted biopsy was performed on approximately 1,140 men with 
suspicious regions identified on pre-biopsy 3T mpMRI along with systematic 12 core biopsy, 
utilizing the ProFuse|Artemis system™. Logistic regression model was used to evaluate 
predictors of Gleason score ≥7, and corresponding nomograms were generated. A total of 
389 men with no previous biopsy and complete records were included for analysis (median 
age 66 years, PSA 4.8 ng/ml, prostate volume 46 cc, PSA density 0.09 ng/ml-cc). PSA density, 
age, and MRI suspicion score predict PCa on mpMRI-targeted and systematic biopsy.  
Niu et al. (36) established that patient age, PI-RADS v2 score and adjusted-PSA 
density were independent predictors for high grade PCa. They validated a nomogram based 
on mpMRI for forecasting high grade PCa, which they felt could reduce unnecessary 
prostate biopsies in patients with PSA 4–10 ng/mL.  
Other work has identified the important role of clinical information as a predictor of 
significant PCa, especially PSA density (37). Logistic regression analyses were performed to 
test different clinical factors as predictors of PCa and build nomograms. An overall of 451 
men were diagnosed with significant PCa, including 187 with a Gleason score of 4 + 3 or 
greater. On ROC curve analyses the predictive power of the developed nomogram from the 
authors for significant PCa showed a higher AUC than that of PI-RADS alone (0.79 vs 0.75, p 
<0.001). The NPV of harbouring PCa increased in men with unsuspicious mpMRI from 79% 
up to 89% when PSA density was 0.15 ng/ml/ml or less. In the repeat biopsy setting the NPV 
of significant PCa increased from 83% to 93%. The NPV to harbour high grade PCa increased 
from 92% up to 98% in the entire cohort. 
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The use of pre-biopsy mpMRI, in conjunction with traditional clinical parameters and 
secondary biomarkers-nomograms, may allow more accurate risk stratification and 
assessment of need for prostate biopsy. The construction of nomograms can provide 
clinicians with simple tools capable of predicting the presence of PCa in the wide spectrum 
of individuals with suspicion of PCa and reduce the number of unnecessary biopsies.  
Table 1 summarises some of the current literature regarding intermediate lesions, 
scale used in the analysis (PI-RADS vs Likert score), percentage of PCa and percentage 
significant PCa.  





The indeterminate MRI is a common finding in men with suspected PCa and 
management of this result is controversial. PI-RADSv2 made an attempt to define 
indeterminate lesions giving fixed criteria, such as moderate hypointensity in the T2-
weighted imaging and focal mildly/moderately hypointense on ADC and isointense/mildly 
hyperintense on high b-value in the diffusion-weighted imaging, but there is variation in 
clinical practice. Men with an indeterminate lesion on mpMRI who undergo biopsy have PCa 
in 12-33 %; of these, 4-12 % is clinically significant. A strategy of close surveillance based on 
PSA monitoring and mpMRI may be offered. This surveillance strategy could result in fewer 
men needing to undergo biopsy, and though early results are promising, long-term results 
for such a strategy are awaited. The use of mpMRI, in conjunction with traditional clinical 
parameters such as PSA density and secondary biomarkers-nomograms, may allow more 
accurate risk stratification and assessment of the need for prostate biopsy in men with 
indeterminate MRIs. Future scoring systems or new version of current systems may also 
affect the outcomes seen for patients. Also, prostate MRI is an expert skill that has a 
learning curve. The threshold required to declare a lesion as indeterminate can vary 
between radiologists of different experience level. Therefore, dedicated training sessions 
should be provided to radiologists reporting prostate MRI so that clinicians can make 
appropriate management decisions based on reliable information. 
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Figure 1: Fifty-one-year-old man presenting with prostate specific antigen of 1.6 ng/ml and a 
suspicious digital rectal examination. The arrows indicate the peripheral zone of the 
prostate on multi-parametric magnetic resonance imaging. There is diffuse, bilateral low 
signal on T2-weighted imaging (A), with blush and diffuse enhancement on dynamic 
contrast enhanced imaging (B). There is only minimal associated restricted diffusion on 
diffusion-weighted imaging (C) and on the apparent diffusion coefficient map (D). The area 








Figure 2: Sixty-eight-year-old man presenting with increasing prostate specific antigen (from 
6 to 12 ng/ml) and three sets of negative biopsies. The arrows indicate an area in the right 
para-sagittal anterior transition zone characterised by low signal on T2-weighted imaging (A) 
and moderate enhancement on dynamic contrast enhanced imaging (B). The lesion is not 
conspicuously bright on long b value sequences on diffusion-weighted imaging (C), but there 
is some associated restricted diffusion on the apparent diffusion coefficient map (D). The 
area was scored as 3/5 on a Likert scale. The subsequent targeted biopsy did not show any 
cancer 
 
